Navigation Links
Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
Date:4/16/2008

GENEVA, Switzerland, April 16 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today announced the appointment of Dr. Dimitri Goundis as Project Director of Clinical Development as the company prepares to enter human clinical trials with its lead Alzheimer's compound within the next 12 months.

Dr. Goundis has more than 20 years experience in the management of clinical trials, including leadership positions at Speedel AG (SWX: SPPN), The Medicines Company (NASDAQ: MDCO) and Roche (SWX: ROG). He has successfully led the development of several medications currently on the market, including SPP 100 (Tekturna/Rasilez), which was licensed by Novartis (NYSE: NVS) and subsequently approved by the US Food and Drug Administration (FDA), the European Commission and the Swiss Agency for Therapeutic Products (Swissmedic), Switzerland's drug and device regulatory agency.

Dr. Goundis will lead the clinical development of ANAVEX's robust pipeline. He will establish a clinical development team as well as select and manage the contract research organizations that will work with ANAVEX to move its drug candidates through clinical trials in preparation for submission to the FDA and other regulatory agencies. Dr. Goundis will be responsible for medicinal chemistry and for galenics, which pertains to the formulation of therapeutic agents into palatable or otherwise practically useful formulations.

"We are honored to welcome Dr. Goundis as a key member of ANAVEX's senior management team and be
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
2. Anavex strengthens Board of Directors
3. Anavex advances drug candidate for treatment of Alzheimers disease
4. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
5. Metabolex Appoints Donald Hill as Chief Financial Officer
6. Biopure Appoints New Independent Auditor
7. Indivumed Appoints Annette Kassen as Vice President Clinical Research
8. ADVENTRX Appoints Vice President of Manufacturing
9. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
10. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
11. Observant LLC Appoints Two New Directors to the Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... the information security firm Symantec released the 11th ... is Symantec's attempt to get out of the day-to-day and ... pretty ominous, according to Dave Cole, a director in the ... the game today is data theft, and the creation of ...
... Cagigal knows the missing link in many software evaluations, ... implementation. , ,Cagigal, chief information technology officer for ... on investment often neglect to factor in the ongoing ... the life of the application. , , David ...
... bioinformatics challenge, a free website has been developed by a ... and Children's Research Institute in Milwaukee to significantly improve diagnostic ... viruses. , ,The possibility of a pandemic has ... avian or bird flu virus, and they have been scrambling ...
Cached Biology Technology:Symantec: Cyber fraudsters look for low-hanging fruit 2Symantec: Cyber fraudsters look for low-hanging fruit 3Symantec: Cyber fraudsters look for low-hanging fruit 4Symantec: Cyber fraudsters look for low-hanging fruit 5Symantec: Cyber fraudsters look for low-hanging fruit 6Symantec: Cyber fraudsters look for low-hanging fruit 7The business case for software applications 2The business case for software applications 3Medical College team creates website for tracking flu 2Medical College team creates website for tracking flu 3
(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... is available in Spanish . , In ... research works that throw light on global warming are of ... atmospheric aerosol, a suspension of solid or liquid particles on ... cooling of the atmosphere. Juan Luis Guerrero Rascado ...
... of Singapore scientists, led by Christopher Wong, Ph.D., have ... of any influenza A virus, including H1NI, with just ... patients. The new method, which enables scientists ... sequence them within a day, was developed at the ...
... MDVariations in both milk feeding and in the weaning ... and they have independent influences on body composition in ... publication in The Endocrine Society,s Journal of Clinical ... Previous studies suggest that the early environment may be ...
Cached Biology News:A research work will be the reference to characterize the climatic impact of desert dust 2Rapid approach to identify influenza A virus mutations and drug resistance developed 2Breastfeeding duration and weaning diet may shape child's body composition 2
... Pyruvate Kinase. This product is ... from other mammalian species but has ... Gives a single precipitin line against ... been shown to react with all ...
... of the COP9 signalosome complex (CSN), a ... processes. The CSN complex is an essential ... by mediating the deneddylation of the cullin ... complex is also involved in phosphorylation of ...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... exhibits very high activity in primer extension ... the quality of the enzyme, each lot ...
Biology Products: